- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07376577
Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP (Anricofen Cipr)
Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial
This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.
This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.
Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.
The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.
The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Longhua Guo
- Número de telefone: 18303733012
- E-mail: 1535732839@qq.com
Locais de estudo
-
-
Henan
-
Xinxiang, Henan, China
- Recrutamento
- The First Affiliated Hospital of Henan Medical University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
**Inclusion Criteria:**
- Aged 18 to 80 years;
- American Society of Anesthesiologists (ASA) physical status I to III;
- Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).
**Exclusion Criteria:**
- Pregnancy or lactation;
- Obstructive sleep apnea (OSA);
- Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
- Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
- Allergy to any of the study drugs;
- Severe cardiac, hepatic, renal, or other major organ diseases;
- Mental or cognitive impairment that prevents cooperation with the assessment;
- Inability to comply with the study protocol or complete follow-up;
- Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Anricofen(HSK21542) 1 μg/kg + Ciprofol
|
Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection. Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. |
|
Comparador Ativo: Sufentanil 0.1 μg/kg + Ciprofol
|
Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively
Prazo: 24 hours after the procedure
|
The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality. |
24 hours after the procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Resting Numerical Rating Scale (NRS) Pain Score
Prazo: At prespecified time points postoperatively
|
Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points. |
At prespecified time points postoperatively
|
|
Total Ciprofol Consumption
Prazo: During the ERCP procedure
|
The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups. |
During the ERCP procedure
|
|
Respiratory and Hemodynamic Adverse Events
Prazo: During the procedure and up to 24 hours postoperatively
|
The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine. |
During the procedure and up to 24 hours postoperatively
|
|
Postoperative Nausea and Vomiting (PONV)
Prazo: Within 24 hours postoperatively
|
The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups. |
Within 24 hours postoperatively
|
|
Serious Adverse Events (SAEs)
Prazo: From enrollment until the end of the study
|
The occurrence, type, and details of serious adverse events will be recorded throughout the study period. |
From enrollment until the end of the study
|
|
Recovery Time
Prazo: From the end of the ERCP procedure to recovery
|
The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups. |
From the end of the ERCP procedure to recovery
|
|
Post-Anesthesia Care Unit (PACU) Length of Stay
Prazo: From PACU admission to PACU discharge
|
The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups. |
From PACU admission to PACU discharge
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- XYFY-IIT-ANES-ERCP-2025-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .